Publisher's Synopsis
Features novel topics that provide different angles and fresh ideas. For example, mTPI is based on a different statistical framework than most current adaptive designs for phase I dose finding trials. The phase I-II seamless design is also fresh with few publications Covers the adaptive subgroup discovery which is trendy, given the recent advance in genomics medicine. It is also highly important to improve the efficiency of the new types of biomarker trials aiming to identify subgroups that have high risks of disease progression or high probabilities of response Discusses some recently debated issues that will stimulate more research and advancement in the adaptive designs. For example, the issue of borrowing strength in phase I dose-finding trials.
